A5084138554- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- Virus-based gene therapy research
- T-cell and B-cell Immunology
- Viral Infectious Diseases and Gene Expression in Insects
- Nanowire Synthesis and Applications
- Monoclonal and Polyclonal Antibodies Research
- Advancements in Semiconductor Devices and Circuit Design
- Protein Degradation and Inhibitors
- Multiple Myeloma Research and Treatments
- Kruppel-like factors research
- Lipid metabolism and disorders
- Cancer Research and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Single-cell and spatial transcriptomics
- Biosimilars and Bioanalytical Methods
- Mesenchymal stem cell research
- Ginkgo biloba and Cashew Applications
- Silicon Carbide Semiconductor Technologies
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Barrier Structure and Function Studies
- Systemic Lupus Erythematosus Research
Guangzhou Institutes of Biomedicine and Health
2015-2025
State Key Laboratory of Respiratory Disease
2016-2025
Chinese Academy of Sciences
2016-2025
Shenzhen University Health Science Center
2025
Shenzhen University
2025
Jinan University
2020-2022
First Affiliated Hospital of Jinan University
2021
University of Chinese Academy of Sciences
2018
In recent years, immunotherapies, such as those involving chimeric antigen receptor (CAR) T cells, have become increasingly promising approaches to non-small-cell lung cancer (NSCLC) treatment. this study, we explored the antitumor potential of prostate stem cell (PSCA)-redirected CAR and mucin 1 (MUC1)-redirected cells in tumor models NSCLC. First, generated patient-derived xenograft (PDX) mouse human NSCLC that maintained antigenic profiles primary tumors. Next, demonstrated expression...
Gastric cancer (GC) is a common in Asia and currently lacks targeted therapy approach. Mesothelin (MSLN) has been reported to be expressed GC tissue could by chimeric antigen receptor (CAR) T cells. targeting CAR-T mesothelioma, lung cancer, breast pancreas cancer. However, the feasibility of using anti-MSLN CAR cells treat remains studied. We verified MSLN expression primary human tissues cell lines then redirected with containing scFv (single-chain variable fragment), CD3ζ, CD28, DAP10...
Abstract Sustained expression of programmed cell death receptor-1 (PD-1) is correlated with the exhaustion T cells, and blockade PD-1 pathway an effective immunotherapeutic strategy for treating various cancers. However, response rates are limited, many patients do not achieve durable responses. Thus, it important to seek additional strategies that can improve anticancer immunity. Here, we report bromodomain extraterminal domain (BET) inhibitor JQ1 inhibits in Jurkat primary T-cell models....
Multiple iterations of chimeric antigen receptors (CARs) have been developed, mainly focusing on intracellular signaling modules. However, the effect non-signaling extracellular modules expansion and therapeutic efficacy CARs remains largely undefined. We generated two versions CAR vectors, with or without a hinge domain, targeting CD19, mesothelin, PSCA, MUC1, HER2, respectively. Then, we systematically compared domains growth kinetics, cytokine production, cytotoxicity T cells in vitro...
Chimeric antigen receptor T cells (CAR-T cells) therapy has been well recognized for treating B cell-derived malignancy. However, the efficacy of CAR-T against solid tumors remains dissatisfactory, partially due to heterogeneity and cell exhaustion in tumor microenvironment. PD-L1 is up-regulated multiple tumors, resulting upon binding its PD-1.Here, we designed a dominant-negative form PD-1, dPD1z, vector containing extracellular transmembrane regions human CAR PD-L1, CARPD-L1z, employs...
T cell infiltration into tumors is essential for successful immunotherapy against solid tumors. Herein, we found that the expression of hyaluronic acid synthases (HAS) was negatively correlated with patient survival in multiple types including gastric cancer. HA impeded vitro anti-tumor activities anti-mesothelin (MSLN) chimeric antigen receptor cells (CAR-T cells) cancer by restricting CAR-T mobility . We then constructed a secreted form human hyaluronidase PH20 (termed sPH20-IgG2)...
Abstract Co-expression of chimeric switch receptors (CSRs) specific for PD-L1 improves the antitumor effects antigen receptor (CAR) T cells. However, trans-recognition between CSRs and expressed by activated CAR cells remain unclear. Here, we design a CSR (CARP), containing transmembrane cytoplasmic signaling domains CD28 but not CD3 ζ chain. We show that CARP enhance activity anti-mesothelin (CARMz) in vitro vivo. In addition, confocal microscopy indicates molecules on CARMz accumulate at...
Abstract Background Gastric cancer is a deadly malignancy and prognostically unfavorable entity with restricted therapeutic strategies available. Prostate stem cell antigen (PSCA) glycosylphosphatidylinositol (GPI)-anchored surface protein widely expressed in bladder, prostate, pancreatic cancers. Existing studies have thoroughly recognized the availability of utilizing anti-PSCA CAR-T cells treatment metastatic prostate non-small-cell lung cancer. However, no previous study has investigated...
Tumor cells and the immunosuppressive tumor microenvironment suppress antitumor activity of T through immune checkpoints, including PD-L1/PD-1 axis. Cytokine-inducible SH2-containing protein (CISH), a member suppressor cytokine signaling (SOCS) family, inhibits JAK-STAT cell receptor (TCR) in natural killer (NK) cells. However, its role regulation checkpoints remains unclear. In this study, we ablated CISH with CRISPR-Cas9 found that sensitivity to TCR stimulation was increased. addition,...
Chimeric antigen receptor (CAR) T cell immunotherapies have shown remarkable efficacy in treating multiple types of hematological malignancies but are not sufficiently effective at solid tumors. NKG2D is a strong activating for NK cells and co-stimulatory cells. signal transduction depends on DNAX-activating protein 10 (DAP10). Here, we introduced the cytoplasmic domain DAP10 into second-generation CARs M28z G28z to generate M28z10 G28z10, which target mesothelin (MSLN) glypican 3 (GPC3),...
Chimeric antigen receptor (CAR) T cells have been successfully used in the therapy of B cell leukemia and lymphoma, but still many challenges their use for treating malignancies, such as lack unique tumor antigens, limitation expansion, need third party donors or genome editing. Therefore, we to find novel targets CAR overcome these challenges. Here, found that both adult T-cell leukemia/lymphoma (ATLL) patients ATLL had increased CCR8 expression did not express CD7. Moreover, targeting...
Chimeric antigen receptor T (CAR-T) cells have emerged as novel and promising immune therapies for the treatment of multiple types cancer in patients with hematological malignancies. There are several key components critical development application CAR-T therapy. First, design CAR vectors can considerably affect aspects physiological functions these cells. Moreover, despite wide use γ-retrovirus lentivirus mediating gene transfer into cells, optimal delivery systems also being developed...
Abstract Background: Chimeric antigen receptor T cells (CAR-T cells) therapy has been well recognized for treating B cell-derived malignancy. However, the efficacy of CAR-T against solid tumors remains dissatisfactory, partially due to heterogeneity and cell exhaustion in tumor microenvironment. PD-L1 is up-regulated multiple tumors, resulting upon binding its PD-1. Methods: Here, we designed a dominant-negative form PD-1 , dPD1z, vector containing extracellular transmembrane regions human...
Abstract Background: Chimeric antigen receptor T cells (CAR-T cells) therapy has been well recognized for treating B cell-derived malignancy. However, the efficacy of CAR-T against solid tumors remains dissatisfactory, partially due to heterogeneity and cell exhaustion in tumor microenvironment. PD-L1 is up-regulated multiple tumors, resulting upon binding its PD-1. Methods: Here, we designed a dominant-negative form PD-1 , dPD1z, vector containing extracellular transmembrane regions human...
Kruppel-like factor 4 (KLF4) is a zinc finger transcription that can regulate diverse cellular physiological functions such as cell growth, death, differentiation, and migration. Recent studies have suggested KLF4 act either suppressor or oncogene for different types of cancers, ranging from solid tumors to leukemia, by regulating target genes involved in tumor proliferation, survival, metastasis, invasiveness, the constitution microenvironment. In most cancer types, has shown ability...